Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: BeiGene
Condition: MSI-H/dMMR Solid Tumors
NCT03736889
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.